Lantern Pharma Inc. (LTRN)
3.90
-0.05 (-1.27%)
At close: Mar 03, 2025, 12:14 PM
No 1D chart data available
| Bid | 3.83 |
| Market Cap | 42.11M |
| Revenue (ttm) | 261.57K |
| Net Income (ttm) | -19.13M |
| EPS (ttm) | -1.78 |
| PE Ratio (ttm) | -2.19 |
| Forward PE | -2.92 |
| Analyst | n/a |
| Ask | 3.99 |
| Volume | 32,884 |
| Avg. Volume (20D) | 106,155 |
| Open | 3.79 |
| Previous Close | 3.95 |
| Day's Range | 3.77 - 3.99 |
| 52-Week Range | 2.79 - 11.99 |
| Beta | 1.60 |
About LTRN
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In ...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 11, 2020
Employees 21
Stock Exchange NASDAQ
Ticker Symbol LTRN
Website https://www.lanternpharma.com
2 months ago
+4.27%
Lantern Pharma shares are trading higher after the...
Unlock content with
Pro Subscription
3 months ago
+0.95%
Lantern Pharma shares are trading higher after the company announced LP-184 received its second fast-track designation status from the FDA for the treatment of triple-negative breast cancer.
